Onco-Innovations Secures Exclusive License for PNKP Inhibitors in Cancer Treatment

Onco-Innovations Limited has announced a significant step forward in cancer treatment with its exclusively-licensed PNKP inhibitors technology. This novel technology is poised to enhance the effectiveness of cancer therapies for a range of cancers including colorectal, breast, and lung cancer. By targeting cancer cells and preventing their DNA repair, the technology addresses the limitations of traditional therapies, which often struggle with targeting tumors and overcoming resistance.

With ongoing developments, Onco-Innovations aims to navigate the challenges faced by conventional treatments. Upon successful completion of U.S. FDA Phase 1 - 3 trials, the company anticipates capturing a portion of the rapidly expanding oncology market, projected to grow to USD 521.60 billion globally by 2033. CEO Thomas O'Shaughnessy highlighted the transformative potential this technology has in improving patient outcomes globally.